Friday, October 16, 2020, 12:00 pm — ZoomGov
The recent outbreak of coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 in December 2019 posed great threats to public health and attracted enormous attention around the world. The morbidity and mortality rates associated with COVID-19 in the United States and Europe are increasing exponentially. To date, there are no clinically approved vaccines or antiviral drugs available for these COVID-19 infections and hence there is urgent demand for effective therapeutics and vaccines to control and eradicate the pandemic. We are using structure-based drug discovery (SBDD) approach to develop anti-COVID-19 drugs by targeting multiple viral targets. In order to ramp up the discovery process, we are screening FDA approved drugs with special attention to other existing antiviral and pathogen-specific drugs. Indeed, we have identified few FDA approved drugs that can inhibit (with moderate potency) one of the SARS-CoV-2 viral protein, main protease (Mpro), which play a key role in the viral replication cycle. In this presentation, we will highlight our efforts on SBDD approach on Mpro as a representative target that includes viral protein production, molecular docking studies, in-vitro binding assay and the co-crystal structure determination.
Hosted by: Ignace Jarrige
15948 | INT/EXT | Events Calendar
Not all computers/devices will add this event to your calendar automatically.
A calendar event file named "calendar.ics" will be placed in your downloads location. Depending on how your device/computer is configured, you may have to locate this file and double click on it to add the event to your calendar.
Event dates, times, and locations are subject to change. Event details will not be updated automatically once you add this event to your own calendar. Check the Lab's Events Calendar to ensure that you have the latest event information.